Kenya's Government and PSK Collaborate on Pharmacy Reforms

Government and PSK Collaborate to Strengthen Pharmacy Reforms and Local Manufacturing In a significant move to improve healthcare services and boost local pharmaceutical manufacturing, the government of Kenya, through the Ministry of Health, has joined forces with the Pharmaceutical Society of Kenya (PSK). This collaboration aims to advance key pharmacy reforms and strengthen the country’s ability to produce medicines domestically. The Principal Secretary for Public Health #HealthcarePolicy #LocalManufacturing #pharmacyreforms #PSK

Government and PSK Collaborate to Strengthen Pharmacy Reforms and Local Manufacturing In a significant move to improve healthcare services and boost local pharmaceutical manufacturing, the government of Kenya, through the Ministry of Health, has joined forces... #Health #HealthcarePolicy #LocalManufacturing #pharmacyreforms #PSK https://lnkd.in/dhbqEmeh

🚨 Important Update in the European Medicines Agency Pharmaceutical Landscape 🚨 The European Medicines Agency Commission has officially withdrawn the marketing authorization for Grastofil, a filgrastim-based medication used to treat neutropenia, effective January 13, 2025. This decision follows a strategic move by Accord Healthcare S.L.U., the marketing authorization holder, who has chosen to cease commercialization of Grastofil due to financial considerations. Grastofil, approved initially in 2013 and granted indefinite validity in 2018, has served as a cost-effective biosimilar alternative to Neupogen, supporting patients with neutropenia, including those undergoing chemotherapy. This withdrawal highlights the complex balance between commercial viability and medical efficacy in the pharmaceutical sector. 💡 Key Points: • Grastofil offered an affordable, effective treatment option for neutropenia • Withdrawal reflects economic reassessment by Accord Healthcare S.L.U. • Healthcare professionals and patients will need to explore alternative therapies • Emphasizes the importance of diverse treatment options in dynamic markets Healthcare providers and patients are encouraged to consult closely to ensure uninterrupted care and adapt treatment plans accordingly. #AccordHealthcare #Biosimilars #EuropeanCommission #HealthcareUpdate #MarketWithdrawal #Neutropenia #OncologyCare #PatientCare #PharmaceuticalNews #Recall #RegulatoryAgencies #MarketAccess #MarketAccessToday

💊 The $445 Billion Healthcare Hero You've Never Heard Of: GENERIC DRUGS 🚨 MIND-BLOWING: 90% of US prescriptions are generics, yet they're only 13.1% of prescription spending. These "copycat" medications are keeping healthcare affordable. Generic drugs = medications equivalent to brand-name products in dose, strength, administration, quality, and use—minus the brand name and massive price tag. 🔥 Why Generics Are Healthcare's Secret Weapon: 💰 80-85% cheaper than brand equivalents ⚖️ Same FDA standards - bioequivalence testing required 🏥 $445B saved in 2023 alone 📊 $3.1T total savings past decade 📈 Staggering Impact Numbers: 90% US prescriptions = generics $6.16 generic copay vs $56.12 brand-name 93% generics cost under $20 91% market share, only 13.1% spending ⚡ Real Success Stories: 🧠 Crestor generic: 99% share, $19.07B saved since 2015 💉 Prilosec generic: 98% share, $12.1B saved since 2001 🩺 Medicare: $137B saved in 2023 ($2,672 per beneficiary) 🏢 Commercial plans: $206B savings 🌟 The Science Behind Savings: Bioequivalence requires: 📊 90% confidence interval (80-125% brand performance) 🔬 Same ingredients, strength, dosage ⚡ Identical absorption rate/extent 🛡️ Rigorous FDA review 💡 Myth-Busting: ❌ "Lower quality" → FDA requires identical standards ❌ "Don't work as well" → 3.5M patient study = no differences ❌ "More side effects" → Studies prove equivalent safety 💼 For Healthcare Pros: Generic mastery enables: ✅ Confident patient counseling on safety/efficacy ✅ Addressing cost barriers to adherence ✅ Bioequivalence vs. therapeutic equivalence explanations ✅ Optimized formulary decisions 🔬 Approval Requirements: Generics must prove: → Pharmaceutical equivalence - same active ingredient → Bioequivalence - identical body performance → Manufacturing standards - FDA facility inspections → Quality assurance - ongoing post-approval monitoring 💼 Economic Multiplier Effect: Every $1 on generics creates: → $4-5 healthcare savings through reduced costs → Increased adherence via affordability → Competition pressure reducing brand prices → Healthcare accessibility for underinsured 🔄 Future Impact: Generic competition drives: → Complex generic innovation → Biosimilar expansion - $12.4B additional savings → $380B global market by 2030 → Healthcare sustainability - cost control 💬 Your Turn: Counsel patients on generic vs. brand? Seen cost barriers affect adherence? Your generic substitution approach? Share below! 👇SR Clinical Research Services 🔗 Every affordable prescription stands on generic manufacturers proving their products work just as well—for fraction of the price. #GenericDrugs #HealthcareCosts #PharmaceuticalSavings #MedicalAccess #Bioequivalence #HealthcareInnovation #PatientCare #HealthcareAffordability #MedicalEconomics #SRClinicalResearchServices

🔍 The European Medicines Agency has completed a comprehensive safety review of omega-3-acid ethyl esters 90, a key component in many medicinal products across the European Medicines Agency Union. This critical periodic safety update report single assessment ensures that treatments for lipid disorders and cardiovascular health meet the highest standards of patient safety and therapeutic efficacy. ⚠️ Key insights include the need for caution regarding potential interactions with anticoagulant medications and reports of mild gastrointestinal effects, highlighting the importance of ongoing monitoring and re-evaluation. This rigorous evaluation underscores the EU’s commitment to proactive pharmacovigilance and maintaining trusted, effective healthcare solutions. 💡 Continuous collaboration between regulatory bodies, healthcare professionals, and pharmaceutical companies is essential to safeguard public health and optimize patient outcomes. #CardiovascularHealth #EuropeanMedicinesAgency #HealthcareInnovation #MedicalReview #Omega3 #PatientSafety #Pharmacovigilance #Recall #RegulatoryAgencies #TherapeuticEfficacy #MarketAccess #MarketAccessToday

This is very big news, and a smart move by the FDA. Ketamine is on the WHO list of essential medicines because it has proven to be a safe and effective anesthetic over 50 years of use. In addition, ketamine shows promise as an antidepressant for treatment resistant depression (when used under appropriate medical supervision, NOT self administration!) Equally if not more exciting, the U.S. military has found that when ketamine is administered in very low, ideally fixed, doses by medics and corpsmen it is an excellent NON-OPIOID analgesic that as effective but safer than morphine for treating severe pain on the battlefield. Based on military and civilian studies, many civilian EMS services are using ketamine “off label” to treat severe pain in emergency situations. For background on this concept, see first box in comments. Congratulations to the FDA and Virginia-based Phlow!

Common Mistakes to Avoid When Ordering Medicines in Odisha Ordering medicines for hospitals, pharmacies, or clinics might seem straightforward — but even small mistakes can lead to supply delays, increased costs, or patient risk. In Odisha’s competitive pharmaceutical market, healthcare providers must be careful when choosing distributors and managing orders. Here are a few critical mistakes to avoid: 🚫 Not verifying distributor licenses or credibility 🚫 Ignoring bulk discounts and minimum order terms 🚫 Overlooking expiry dates and storage standards 🚫 Failing to track order status 🚫 Skipping contract and pricing reviews Partnering with reliable distributors like Garg Pharma helps prevent these issues and ensures timely, safe, and transparent delivery of medicine across Odisha. Read the full guide here: https://lnkd.in/e8ZmsZtT #GargPharma #PharmaDistribution #OdishaHealthcare #MedicineSupply #PharmaIndia #GenericMedicines #DrugDistributor #HealthcareLogistics #PharmaBusiness #PharmaNetwork

Off-patent medicines play a central role in improving healthcare efficiency, accessibility, and sustainability across Latin America and the Caribbean. At the Inter-American Development Bank we have developed a Generic and Biosimilar Medicines Policy Assessment Tool, designed to help countries assess and strengthen their pharmaceutical policies. 🔗 You can access the publication here: https://lnkd.in/e2HqBn4G Javier Guzman Veronika Wirtz Jaime Espin Ferdinando Regalia #HealthPolicy #Medicines #Generics #Biosimilars #SmartSpending #IDB

Pharmacists play diverse roles across various fields — from regulatory, community, and hospital settings to emerging areas of expertise. One of the evolving and transitioning paths in the pharmaceutical industry today is in Business Development, where pharmacists apply their scientific knowledge, regulatory understanding, and communication skills to drive strategic growth and global partnerships. At Getmeds, our esteemed Business Development team works hand in hand with our Regulatory Affairs department to ensure strong collaborations only with trusted, high-quality manufacturers and reputable global suppliers. This partnership enables us to provide reliable access to essential medicines—especially for cancer, hematology, and rare diseases—to patients in the Philippines, where we have one of our strongest presences. Our continuous participation in international conventions such as IPHEX, CPHI, and other prestigious pharmaceutical events reflects our unwavering commitment to global standards, innovation, and our mission to make quality healthcare accessible to every Filipino. Our team proudly serves as a bridge between global healthcare partners and Filipino patients, ensuring life-changing treatments reach those who need them most. #Pharmaceuticals #Pharmacist #PatientCare #Healthcare

Transforming local pharmaceutical systems is crucial for ensuring universal access to essential European Medicines Agency. New research highlights the often-overlooked role of local pharmaceutical systems, emphasizing their unique functions in governance, supply management, financing, resource development, dispensing, and performance monitoring. By developing a robust and innovative framework, experts provide a practical tool to evaluate and improve these systems, ensuring European Medicines Agency are not only accessible but used appropriately for better healthcare outcomes. This breakthrough underscores the necessity of coordinated local efforts and comprehensive analysis to empower policymakers and healthcare providers alike. As we advance, adopting this structured methodology offers a strategic pathway to enhance medicine access and optimize healthcare delivery on the ground. 🔬💊📈 #AccessToMedicine #HealthPolicy #HealthcareInnovation #HealthcareTransformation #LocalHealthSystems #MedicineAccess #PharmaceuticalSystems #Publications #RegulatoryAgencies #UniversalHealthCoverage #MarketAccess #MarketAccessToday